Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company
developing a proprietary therapeutic tissue treatment based on its
Nano-Pulse Stimulation (NPS) platform, today announced that the Company
will report second quarter 2018 operational highlights and financial
results on Tuesday, July 31, 2018. Pulse Biosciences management will
host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30
p.m. Pacific Time (PT).

Analysts and investors can participate in the conference call by dialing
(844) 494-0190 (domestic) and (508) 637-5580 (international) using the
conference ID# 3295809. The webcast of the conference call can be
accessed live on the Investor Relations section of the Pulse Biosciences
website at www.pulsebiosciences.com.

About Pulse Biosciences

Pulse Biosciences is a publicly listed clinical stage electroceutical
company pursuing multiple clinical applications of its proprietary
Nano-Pulse Stimulation technology. Nano-Pulse Stimulation (NPS) is a
non-thermal, precise, focal tissue treatment technology comprised of
nanosecond (billionth of a second) range pulsed electric fields that
directly affect the cell membrane and intracellular structures and
initiates cell death in treated cells. The initiation of cell death by
NPS results in a minimal inflammatory response, which improves healing
outcomes and supports the replacement of treated tissue cells with
healthy tissue cells. NPS’ unique mechanism of action to initiate cell
death has the potential to significantly benefit patients for multiple
medical applications in dermatology, immune-oncology, and in other
unique tissue targets. In cancerous lesions, NPS has been shown in
preclinical models to induce immunogenic cell death (ICD), which exposes
the unique antigens of the treated cells to the immune system and
enrolls immune system cells, such as cytotoxic T-cells to mount an
adaptive immune response. More information is available at www.pulsebiosciences.com.


Investor Relations:
Pulse Biosciences, Inc.
Brian Dow
Vice President and Chief Financial Officer
Gitanjali Jain Ogawa, 646-378-2949